Who are NEPINALONE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aricept, Naftin, Cefaprin, Gocovri, Aralen, Lamictal.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nepinalone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

NEPINALONE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NEPINALONE (NEPINALONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nepinalone. Area: Pain.

phase 2 nepinalone Sigma non-opioid intracellular receptor 1 Pain Small molecule Live · refreshed every 30 min

Target snapshot

NEPINALONE (NEPINALONE). Nepinalone works by binding to the Sigma non-opioid intracellular receptor 1, which helps to reduce coughing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NEPINALONE TARGET	NEPINALONE		phase 2	nepinalone	Sigma non-opioid intracellular receptor 1
Aricept	DONEPEZIL	Eisai	marketed	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01
Naftin	NAFTIFINE	Legacy Pharma	marketed	Allylamine Antifungal	Sigma non-opioid intracellular receptor 1	1988-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	marketed	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Gocovri	AMANTADINE	Endo	marketed	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1	1968-01-01
Aralen	CHLOROQUINE	Sanofi	marketed	Antimalarial	Sigma non-opioid intracellular receptor 1	1949-01-01
Lamictal	lamotrigine	GSK	marketed	Anti-epileptic Agent [EPC]	5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-01-07 — Lamictal · 8637512 · Formulation · US
2040-05-29 — Lamictal · 11596634 · Method of Use · US
2040-05-29 — Lamictal · 11612566 · Method of Use · US

Sponsor landscape (nepinalone class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NEPINALONE — Competitive Intelligence Brief. https://druglandscape.com/ci/nepinalone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing